Associations - dactolisib (RTB101)

BRAF mutation	Melanoma	BRAF mutation	Melanoma	selumetinib + RTB101 Sensitive: C3 – Early Trials selumetinib + RTB101 Sensitive : C3	selumetinib + RTB101 Sensitive: C3 – Early Trials selumetinib + RTB101 Sensitive : C3
MLL-MLLT1 fusion	B Acute Lymphoblastic Leukemia	MLL-MLLT1 fusion	B Acute Lymphoblastic Leukemia	RTB101 Sensitive: C4 – Case Studies RTB101 Sensitive : C4	RTB101 Sensitive: C4 – Case Studies RTB101 Sensitive : C4
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
STK11 mutation	Lung Cancer	STK11 mutation	Lung Cancer	dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical dasatinib + selumetinib + RTB101 Sensitive : D	dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical dasatinib + selumetinib + RTB101 Sensitive : D
KRAS mutation	Lung Cancer	KRAS mutation	Lung Cancer	dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical dasatinib + selumetinib + RTB101 Sensitive : D	dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical dasatinib + selumetinib + RTB101 Sensitive : D
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
BRAF V600	Colorectal Cancer	BRAF V600	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
NRAS G12	Colorectal Cancer	NRAS G12	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
NRAS G12	Colorectal Cancer	NRAS G12	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
NRAS G13	Colorectal Cancer	NRAS G13	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
NRAS G13	Colorectal Cancer	NRAS G13	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
PIK3CA H1047	Colorectal Cancer	PIK3CA H1047	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
PIK3CA H1047	Colorectal Cancer	PIK3CA H1047	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
PIK3CA E542	Colorectal Cancer	PIK3CA E542	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
PIK3CA E542	Colorectal Cancer	PIK3CA E542	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
PIK3CA E545	Colorectal Cancer	PIK3CA E545	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
PIK3CA E545	Colorectal Cancer	PIK3CA E545	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
PIK3CA E546	Colorectal Cancer	PIK3CA E546	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
PIK3CA E546	Colorectal Cancer	PIK3CA E546	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
KRAS Q61	Colorectal Cancer	KRAS Q61	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
KRAS Q61	Colorectal Cancer	KRAS Q61	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D	selumetinib + RTB101 Sensitive: D – Preclinical selumetinib + RTB101 Sensitive : D
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
PIK3CA mutation	Endometrial Cancer	PIK3CA mutation	Endometrial Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
PTEN mutation	Endometrial Cancer	PTEN mutation	Endometrial Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	RTB101 + GC-1118A Sensitive: D – Preclinical RTB101 + GC-1118A Sensitive : D	RTB101 + GC-1118A Sensitive: D – Preclinical RTB101 + GC-1118A Sensitive : D
AR expression	Breast Cancer	AR expression	Breast Cancer	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D	RTB101 Sensitive: D – Preclinical RTB101 Sensitive : D
KRAS G12R	Thyroid Gland Medullary Carcinoma	KRAS G12R	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D
BRAF mutation	Thyroid Gland Medullary Carcinoma	BRAF mutation	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D
PTEN mutation	Thyroid Gland Medullary Carcinoma	PTEN mutation	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D	RTB101 + RAF265 Sensitive: D – Preclinical RTB101 + RAF265 Sensitive : D

dactolisib (RTB101)

Associations
(43)

Associations
(43)

dactolisib (RTB101)

Associations(43)

Associations(43)

Associations
(43)

Associations
(43)